Physician profile
Seema Bery
NPI 1871526632
$644.04
in general payments reported to CMS, 2019-2025
14 companies · $49.68 in 2025
The $49.68 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.34 · 2020: $14.12 · 2021: $82.09 · 2022: $124 · 2023: $174 · 2024: $153 · 2025: $49.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $376.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $147.93 | 2021-2024 | |
| Pfizer INC. | $112.21 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $73.31 | 2023-2025 | Rexulti, Nuedexta |
| Jazz Pharmaceuticals INC. | $47.70 | 2021-2022 | |
| Ucb, INC. | $47.34 | 2019 | |
| Lilly USA, LLC | $43.92 | 2022-2025 | Amyvid, Kisunla |
| Abbott Laboratories | $35.29 | 2023-2024 | Proclaim, Eterna |
| Eisai INC. | $34.00 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $31.13 | 2022 | |
| Lundbeck LLC | $17.22 | 2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $16.42 | 2024 | Lokelma |
| Neurelis, INC. | $14.62 | 2023 | Valtoco |
| Biogen, INC. | $11.75 | 2021 | |
| Acadia Pharmaceuticals INC | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Bery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.